Oral retinoids and pregnancy

Medical Journal of Australia

Volumn 165, Issue 3, 1996, Pages 164-167

  Chan, Annabelle ^a,b,c   Hanna, Marshall ^f   Abbott, Malcolm ^a,d,e   Keane, Rosemary J ^a,b  

^a South Australian Health Commission   (Australia)

^b Pregnancy Outcome Unit   (Australia)

^c WOMEN S AND CHILDREN S HOSPITAL   (Australia)

^d Therapeutic Goods Section   (Australia)

^e Territory Health Services   (Australia)

^f FLINDERS MEDICAL CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; CHOLESTEROL; ETRETIN; ETRETINATE; ISOTRETINOIN; LIPID; RETINOID; TRIACYLGLYCEROL;

ACNE CYSTICA; ALOPECIA; AMINOTRANSFERASE BLOOD LEVEL; ANKYLOSING HYPEROSTOSIS; ARTHRALGIA; CHOLESTEROL BLOOD LEVEL; DEPRESSION; DYSKERATOSIS; FEMALE; HEADACHE; HEPATITIS; HUMAN; INFORMED CONSENT; INTRACRANIAL HYPERTENSION; LIPID BLOOD LEVEL; MYALGIA; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; PATIENT COUNSELING; PATIENT EDUCATION; PATIENT MONITORING; PATIENT SELECTION; PRACTICE GUIDELINE; PREGNANCY; PREGNANCY TEST; PRESCRIPTION; PRURITUS; SHORT SURVEY; TERATOGENICITY; TRIACYLGLYCEROL BLOOD LEVEL; VISUAL IMPAIRMENT; XEROSTOMIA;

EID: 0029812335     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.1996.tb124895.x     Document Type: Short Survey

References (20)

1. Australian Drug Evaluation Committee. Medicines in pregnancy. An Australian categorisation of risk of drug use in pregnancy. 2nd ed. Canberra: AGPS, 1992.
2. Chalmers RJG. Retinoid therapy - a real hazard for the developing embryo. Br J Obstet Gynaecol 1992; 99: 276-278.
3. Saurat J-H. Side effects of systemic retinoids and their clinical management. J Am Acad Dermatol 1992; 27: S23-S28.
4. Lammer EJ, Chen DT, Hoar RM, et al. Retinoic acid embryopathy. N Engl J Med 1985; 313: 837-841.
5. Rosa FW, Wilk AL, Kelsey FO. Teratogen update: vitamin A congeners. Teratology 1986; 33: 355-364.
6. Teratology Society: recommendations for isotretinoin use in women of childbearing potential. Teratology 1991; 44: 1-6.
7. Dai WS, LaBraico JM, Stern RS. Epidemiology of isotretinoin exposure during pregnancy. J Am Acad Dermatol 1992; 26: 599-606.
8. Dai WS, Hsu M-A, Itri LM. Safety of pregnancy after discontinuation of isotretinoin. Arch Dermatol 1989; 125: 362-365.
9. Geiger J-M, Baudin M, Saurat J-H. Teratogenic risk with etretinate and acitretin treatment. Dermatology 1994; 189: 109-116.
10. Hogan DJ, Strand LM, Lane PR. Isotretinoin therapy for acne: a population-based study. Can Med Assoc J 1988; 138: 47-50.
11. Lee M, Cooper A. Survey of Australian isotretinoin prescribing. Australas J Dermatol 1991; 32: 13-16.
12. Chan A, Keane RJ, Hanna M Abbott M. Terminations of pregnancy for exposure to oral retinoids in South Australia, 1985-1993. Aust NZJ Obstet Gynaecol 1995; 35: 422-426.
13. Eurocat. Surveillance of the retinoic acid embryopathy: a pharmacy based study. Eurocat Newsletter December 1992; 6(4).
14. Doering PL, Araujo OE, Frohnapple DJ, et al. Patterns of prescribing isotretinoin: focus on women of childbearing potential Am Pharmacother 1992; 26: 155-161.
15. Mitchell AA, Van Bennekom CM, Louik C. A pregnancy-prevention program in women of childbearing age receiving isotretinoin. N Engl J Med 1995; 333: 101-106.
16. Pastuszak A, Koren G, Rieder MJ. Use of the retinoid pregnancy prevention program in Canada: patterns of contraception use in women treated with isotretinoin and etretinate. Reprod Toxicol 1994; 8: 63-68.
17. Kovacs G. Oral contraceptives - can we make them more effective? Med J Aust 1993; 159: 224-225.
18. Ceyrac DL, Serfaty D, Lefrancg H. Retinoids and contraception. Dermatology 1992; 184: 161-170.
19. Sturkenboom MCJM, de Jong-van den Berg LTW, van Voorst-Vader PC, et al. Inability to detect plasma etretinate and acitretin is a poor predictor of the absence of these teratogens in tissue after stopping acitretin treatment. BrJ Clin Pharmacol 1994; 38: 229-235.
20. Rothman K, Moore LL, Singer MR, et al. Teratogenicity of high vitamin A intake. N Engl J Med 1995; 333: 1369-1373.